Starpharma Holdings Limited (ASX: SPL) released investor’s presentation that it will be presenting in Citi Conference held today. It is 10th Annual Australian and New Zealand Investment Conference held in Sydney, that brings together 65 ASX listed companies with over 700 investors and fund managers.
Starpharma presents a Unique proprietary polymer platform that is engaged in manufacturing of dendrimer products. It operates VivaGel and DEP under which more that 100 patented products are registered.
Its products range includes patented VivaGel BV, VivaGel Condom, DEP internal Products and DEP Partnered products. The company has shown some significant track record of commercialization including VivaGel BV license revenue from Mundipharma for multiple regions like Europe, Russia, Asia, Middle East; advanced US negotiations for VivaGel BV which has been approved in Australia and Europe, awaiting launch and expecting US FDA approval. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Multi-product global partnerships for DEP platform including with AstraZeneca has enabled the company to significantly accelerate its path to market while managing investment risk. In recent announcement it declared that AstraZeneca’s first patent application on Starpharma’s DEP dendrimer with its Bcl2/xL inhibitors got published by the World Intellectual Property organization. The conjugates of patent named DEP Bcl2/xL can treat several cancers including leukemias.
Recently Starpharma’s proprietary DEP irinotecan registered 100% tumor regression and survival in a human pancreatic cancer model. The results were based on the study that compared human pancreatic tumor response to standard irinotecan, Camptosar, and to Starpharma’s DEP irinotecan which eventually succeeded.
Company’s loss from continuing operations was $10.3 million, 32% lower than previous year’s $15.2 million loss. It was because FY18 total revenue and income of Starpharma increased 39% to $5 million from $3.6 million in FY17. However, the bottom line reported loss of $10.3 million compared to previous year’s profit of $8.2 million which was broadly derived from sale of agrochemicals business in FY17.
As at 30 June 2018, Starpharma’s cash was $51.3 million.
In today’s trading session Starpharma’s share price has gone up 3.86% to $1.480 on 17 October 2018 with market capitalization of $529.03 million. The stock has seen a performance change of +9.20% over the past one year and in the last three month it has gone as high as 24.45%.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.